RxDoctor Payments Data

Jauhna Deutsch, PA

Medical · Newburgh, INNPI 1467400945

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 172 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations.

$3,615in general payments, 2019–2025

Across 172 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$549
  • Johnson & Johnson$435
  • Abbott$395
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$339
  • Boehringer Ingelheim$327
  • Atricure, Inc.$242
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$3,615100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,615 in reported general payments places this provider in the 80th percentile of 273 medical providers in Indiana.

See all medical providers in Indiana

Medicare billing

Part B allowed, 2024
$112,570
Medicare patients
877
Services billed
1,328

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban353$401,766
XareltoRivaroxaban63$82,036
MultaqDronedarone Hcl54$73,941
Dofetilide170$22,441
Metoprolol Succinate710$9,396
Amiodarone Hcl253$4,399
Diltiazem 24hr Er (Cd)Diltiazem Hcl219$4,141
Mexiletine Hcl33$2,419
Propafenone Hcl ErPropafenone Hcl13$1,976
Propafenone Hcl12$1,471
Midodrine Hcl21$1,064
SotalolSotalol Hcl67$929
Carvedilol117$829
Digoxin29$609
Flecainide Acetate17$515

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$202$401,766353 claims
Johnson & JohnsonXarelto$435$82,03663 claims
Sanofi-aventis U.S. LLCMultaq$147$73,94154 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 273 medical providers in Indiana.

Other medical in Newburgh

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →